| Biologic Therapy |
1 |
1 |
| CAR-T |
0 |
0.74 |
| Stem Cell Research and Therapy |
0 |
0.74 |
| Antineoplastic Drug |
0 |
0.49 |
| Prognosis |
0 |
0.42 |
| Monoclonal Antibody |
0 |
0.35 |
| Transplantation |
0 |
0.35 |
| Cell Transplantation |
0 |
0.34 |
| Healthcare and Medical Technology |
0 |
0.3 |
| Clinical Research |
0 |
0.28 |
| Targeted Cancer Therapy |
0 |
0.22 |
| Cancer |
0 |
0.21 |
| Mantle Cell Lymphoma |
0 |
0.16 |
| Blood |
0 |
0.14 |
| Chemotherapy |
0 |
0.14 |
| Lymphoma |
0 |
0.14 |
| Tyrosine Kinase Inhibitor |
0 |
0.1 |
| Adverse Effects |
0 |
0.07 |
| Antigens |
0 |
0.07 |
| Board Certification |
0 |
0.07 |
| Lymph Node |
0 |
0.07 |
| Patient Safety |
0 |
0.07 |
| Proteasome Inhibitor |
0 |
0.07 |
| Receptors |
0 |
0.07 |
| Referral |
0 |
0.07 |
| Remission |
0 |
0.07 |
| Tyrosine Kinase |
0 |
0.07 |